Hormones: Androgens, antiandrogens, anabolic steroids, estrogens - Unapproved uses or indications

Clinics in Dermatology

Volumn 18, Issue 1, 2000, Pages 55-61

  Gunes, Ali Tahsin ^a   Fetil, Emel ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANABOLIC AGENT; ANDROGEN; ANTIANDROGEN; BETAMETHASONE; BROMOCRIPTINE; CALCITRIOL; CORTICOTROPIN; CYPROTERONE; DANAZOL; DOPAMINE; ESTRADIOL; FLUTAMIDE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HYDROXYPROGESTERONE; KETOCONAZOLE; LIAROZOLE; MEDROXYPROGESTERONE; OCTREOTIDE; PREDNISOLONE; PROGESTERONE; PROPYLTHIOURACIL; SOMATOSTATIN; SPIRONOLACTONE; STANOZOLOL; TAMOXIFEN; THYROID HORMONE; TRIAMCINOLONE; UNINDEXED DRUG;

ACNE; ALOPECIA; DERMATITIS; DISCOID LUPUS ERYTHEMATOSUS; DRUG APPROVAL; DRUG INDICATION; HIRSUTISM; HUMAN; PRIORITY JOURNAL; REVIEW; SCLERODERMA;

ADRENAL CORTEX HORMONES; ANABOLIC AGENTS; ANDROGEN ANTAGONISTS; ANDROGENS; DERMATOLOGIC AGENTS; DRUG APPROVAL; DRUG UTILIZATION; ESTROGENS; HORMONES; HUMAN GROWTH HORMONE; HUMANS; SKIN DISEASES; THYROID HORMONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0033973091     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(99)00094-2     Document Type: Review

References (72)

1. Committee on Drugs. Unapproved uses of approved drugs: The physician, the package insert, and the Food and Drug Administration: Subject review. Pediatrics 1996;98:143-5.
2. Wilson J.D. Androgens. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1441-1457 McGraw-Hill, New York.
3. Hay R.J., Greaves M.W., Warin A.P. Systemic therapy. Champion R.H., Burton J.L., Burns D.A., Breathnach S.M. Rook/Wilkinson/Ebling Textbook of dermatology. 1998;3311-3348 Blackwell Science, Oxford.
4. Freinkel R.K. Other endocrine diseases. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's Dermatology in general medicine. 1999;1976-1986 McGraw-Hill, New York.
5. Jurzyk R.S., Spielvogel R.L., Rose L.I. Antiandrogens in the treatment of acne and hirsutism. Am Fam Physician. 45:1992;1803-1806.
6. Lookingbill D.P., Marks J.G. Principles of dermatology. 1993;11-27 W.B. Saunders, Philadelphia.
7. Rumack BH. Drugdex (CD-ROM). Micromedex Inc., 1999.
8. Joura E.A., Zeisler H., Bancher-Todesca D., et al. Short-term effects of topical testosterone in vulvar lichen sclerosus. Obstet Gynecol. 89:1997;297-299.
9. Wright A.J. Testosterone pellet implant therapy for lichen sclerosus. Mo Med. 90:1993;711-713.
10. Van-Vollenhoven R.F., McGuire J.L. Estrogen, progesterone, and testosterone Can they be used to treat autoimmune diseases? Cleve Clin J Med. 61:1994;276-284.
11. Insiripong S., Chanchairujira T., Bumpenboon T. Danazol for thrombocytopenia in pregnancy with underlying systemic lupus erythematosus. J Med Assoc Thai. 79:1996;330-332.
12. Duhra P., Holmes J., Porter D.I. Discoid lupus erythematosus associated with hereditary angioneurotic oedema. Br J Dermatol. 123:1990;241-244.
13. Hsiao G.H., Chiu H.C. Low-dose danazol in the treatment of livedoid vasculitis. Dermatology. 194:1997;251-255.
14. Jasonni V.M., Bulletti C., Naldi S., et al. Treatment of hirsutism by an association of oral cyproterone acetate and transdermal 17β-estradiol. Fertil Steril. 55:1991;742-745.
15. Fugére P., Percival-Smith R.K.L., Lussier-Cacan S., et al. Cyproterone acetate/ethinyl estradiol in the treatment of acne A comparative dose-response study of the estrogen component . Contraception. 42:1990;225-235.
16. Wishart J.M. An open study of triphasil and diane-50 in the treatment of acne. Australas J Dermatol. 32:1991;51-54.
17. Tolino A., Petrone A., Sarnacchiaro F., et al. Finasteride in the treatment of hirsutism New therapeutic perspectives . Fertil Steril. 66:1996;61-65.
18. Spinucci G, Pasquali R. [Finasteride: A new drug for the treatment of male hirsutism and androgenetic alopecia?]. Clin Ter 1996;147:305-15.
19. Grigoriou O., Papadias C., Konidaris S., et al. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism A randomized controlled trial . Gynecol Endocrinol. 10:1996;119-123.
20. Shaw J.C. Antiandrogen and hormonal treatment of acne. Dermatol Clin. 14:1996;803-811.
21. Sciarra F., Toscano V., Concolino G., et al. Antiandrogens Clinical applications . J Steroid Biochem Mol Biol. 37:1990;349-362.
22. Wong I.L., Morris R.S., Chang L., et al. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute woman. J Clin Endocrinol Metab. 80:1995;233-238.
23. Schmidt J.B. Other antiandrogens. Dermatology. 196:1998;153-157.
24. Neuber K., Kroger S., Gruseck E., et al. Effects of pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN-gamma) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res. 288:1996;532-536.
25. Burton J.L., Holden C.A. Eczema, lichenification and prurigo. Champion R.H., Burton J.L., Burns D.A., Breathnach S.M. Rook/Wilkinson/Ebling Textbook of dermatology. 1998;629-680 Blackwell Scientific, Oxford.
26. Dockx P., Decree J., Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis An open study with oral liarozole . Br J Dermatol. 133:1995;426-432.
27. van-Pelt J.P., de-Jong E.M., de-Bakker E.S., et al. Effects of systemic treatment with liarozole on cutaneous inflammation, epidermal proliferation and differentiation in extensive plaque psoriasis. Skin Pharmacol Appl Skin Physiol. 11:1998;70-79.
28. Williams C.L., Stancel G.M. Estrogens and progestins. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1411-1440 McGraw-Hill, New York.
29. Venturoli S., Ravaioli B., Bagnoli A., et al. Contraceptive and therapeutic effectiveness of two low-dose ethinylestradiol and cyproterone acetate regimens in the treatment of hirsute patients. Eur J Contracept Reprod Health Care. 3:1998;29-33.
30. Castelo-Branco C., Martinez-de-Osaba M.J., Pons F., et al. Gonadotropin-releasing hormone analog plus an oral contraceptive containing desogestrel in women with severe hirsutism Effects on hair, bone, and hormone profile after 1-year use . Metabolism. 46:1997;437-440.
31. Simberg N., Tiitinen A., Silfvast A., et al. High bone density in hyperandrogenic women Effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement . J Clin Endocrinol Metab. 81:1996;646-651.
32. Lemay A., Faure N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism A pilot study . J Clin Endocrinol Metab. 79:1994;1716-1722.
33. Azziz R., Ochoa T.M., Bradley E.L., et al. Leuprolide and estrogen versus oral contraceptive pills for the treatment of hirsutism A prospective randomized study . J Clin Endocrinol Metab. 80:1995;3406-3411.
34. Wallace M.L., Smoller B.R. Estrogen and progesterone receptors in androgenic alopecia versus alopecia areata. Am J Dermatopathol. 20:1998;160-163.
35. Seo W., Ogasawara H., Sakagami M. Chemohormonal therapy for malignant melanomas of the nasal and paranasal mucosa. Rhinology. 35:1997;19-21.
36. Bezwoda W.R. The treatment of disseminated malignant melanoma with special reference to the role of interferons, vinca alkaloids and tamoxifen. Cancer Treat Rev. 23:1997;17-34.
37. Hirota T. Ultrastructural study of anti-tumor effects of tamoxifen in two malignant melanoma patients. J Dermatol. 24:1997;441-450.
38. Schimmer B.P., Parker K.L. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1459-1485 McGraw-Hill, New York.
39. Iyengar B., Misra R.S., Subalakshmi. ACTH acts directly on melanocytes to stimulate melanogenesis - An in vitro study. Indian J Pathol Microbiol. 38:1995;399-402.
40. Braun-Falco O., Plewig G., Wolff H.H., et al. Dermatology. 1991;13-60 Springer-Verlag, Berlin.
41. Daoud M.S., Pittelkow M.R. Lichen planus. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's Dermatology in general medicine. 1999;561-577 McGraw-Hill, New York.
42. Silverman S. Jr, Gorsky M., Lozada-Nur F., et al. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg Oral Med Oral Pathol. 72:1991;665-670.
43. Lomonosov KM, Stenina MA, Ivanov OL. [Proliferative activity of peripheral blood lymphocytes and evaluation of the effectiveness of drugs in lichen ruber planus]. Klin Lab Diagn 1994;3:39-41.
44. Uesugi Y., Aiba S., Usuba M., et al. Oral prednisone in the treatment of acne agminata. Br J Dermatol. 134:1996;1098-1100.
45. Dahl M.V. Granuloma annulare. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's Dermatology in general medicine. 1999;1152-1157 McGraw-Hill, New York.
46. Wolff K., Stingl G. Pyoderma gangrenosum. Freedberg I.M., Eisen A.Z., Wolff K., et al. Fitzpatrick's Dermatology in general medicine. 1999;1140-1148 McGraw-Hill, New York.
47. Goudet P., Pillon D., Bensa F., et al. [Peristomal pyoderma gangrenosum after colectomy for Crohn disease Successful medical treatment] . Ann Chir. 46:1992;525-529.
48. Tu J.H., Eisen A.Z. Scleroderma. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's Dermatology in general medicine. New York: McGraw-Hill. 1999;2023-2033.
49. Dunnill M.G., Black M.M. Sclerodermatous syndrome after occupational exposure to herbicides - Response to systemic steroids. Clin Exp Dermatol. 19:1994;518-520.
50. Mizutani H., Tanaka H., Okada H., et al. Palindromic morphea Multiple recurrence of morphea lesions in a case of systemic sclerosis . J Dermatol. 19:1992;298-301.
51. Blanche P., Bachmeyer C., Mikdame M., et al. Scleroderma, polymyositis, and hairy cell leukemia. J Rheumatol. 22:1995;1384-1385.
52. Ortiz-Alvarez O., Cabral D., Prendiville J.S., et al. Intestinal pseudo-obstruction as an initial presentation of systemic sclerosis in two children. Br J Rheumatol. 36:1997;280-284.
53. Farwell A.P., Braverman L.E. Thyroid and antithyroid drugs. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1383-1409 McGraw-Hill, New York.
54. Rumbyrt J.S., Katz J.L., Schocket A.L. Resolution of chronic urticaria in patients with thyroid autoimmunity. J Allergy Clin Immunol. 96:1995;901-905.
55. Dreyfus D.H., Schocket A.L., Milgrom H. Steroid-resistant chronic urticaria associated with antithyroid microsomal antibodies in a nine-year-old boy. J Pediatr. 128:1996;576-578.
56. Elias A.N., Barr R.J., Rohan M.K., et al. Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions. Int J Dermatol. 34:1995;280-283.
57. Elias A.N., Goodman M.M., Liem W.H., et al. Propylthiouracil in psoriasis Results of an open trial . J Am Acad Dermatol. 29:1993;78-81.
58. Weller P.A. Psoriasis. Med J Aust. 165:1996;216-221.
59. Marcus R. Agents affecting calcification and bone turnover. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1519-1546 McGraw-Hill, New York.
60. Perez A., Raab R., Chen T.C., et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for treatment of psoriasis. Br J Dermatol. 134:1996;1070-1078.
61. Boisseau-Garsaud AM, Legrain V, Hehunstre JP, et al. [Treatment of psoriasis by oral calcitriol: A study of 5 cases and review of the literature]. Ann Dermatol Venereol 1993;120:669-74.
62. Carlberg C., Saurat J.H. Vitamin D-retinoid association Molecular basis and clinical applications . J Investig Dermatol Symp Proc. 1:1996;82-86.
63. Ascoli M., Segaloff D. Adenohypophyseal hormones and their hypothalamic releasing factors. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W. Goodman Gilman's The pharmacological basis of therapeutics. 1996;1363-1382 McGraw-Hill, New York.
64. Rasmussen L.H., Jensen L.T., Avnstorp C., et al. Collagen types I and III propeptides as markers of healing in chronic leg ulcers A noninvasive method for the determination of procollagen propeptides in wound fluid - Influence of growth hormone . Ann Surg. 216:1992;684-691.
65. Gilbert C. Major human cancers are preventable Physiological stimuli induce a dopamine-thyroid-immune efficient mechanism . Eur J Cancer Prev. 6:1997;269-276.
66. Sugumaran M. Oxidation of 3,4-dihydroxybenzylamine affords 3,4-dihydroxybenzaldehyde via the quinone methide intermediate. Pigment Cell Res. 8:1995;250-254.
67. Eulry F, Mayaudon H, Lechevalier D, et al. [Treatment of rheumatoid psoriasis with bromocriptine]. Presse Med 1995;18:1642-4.
68. Buskila D., Sukenik S., Holcberg G., et al. Improvement of psoriatic arthritis in a patient treated with bromocriptine for hyperprolactinemia. J Rheumatol. 18:1991;611-612.
69. Talme T., Schultzberg M., Sundqvist K.G., et al. Colocalization of somatostatin- and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin. Acta Derm Venereol. 77:1997;338-342.
70. Johansson O., Hilliges M., Talme T., et al. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment. Acta Derm Venereol. 74:1994;106-109.
71. Scholzen T., Armstrong C.A., Bunnett N.W., et al. Neuropeptides in the skin Interactions between the neuroendocrine and the skin immune systems . Exp Dermatol. 7:1998;81-96.
72. Soudah H.C., Hasler W.L., Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med. 325:1991;1461-1467.